Cytokinetics Starts Trial For CK-586 In HFpEF
Cytokinetics, Inc. (CYTK), a biopharmaceutical company focused on muscle biology, on Monday announced the launch of the AMBER-HFpEF ...
STAT8d
Cytokinetics is not looking to be acquired, CEO says
The CEO of Cytokinetics says the company is not for sale. That doesn't mean it would turn away potential suitors.
This Cytokinetics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday
Canaccord Genuity analyst Caitlin Burrows initiated coverage on Orthofix Medical Inc. OFIX with a Buy rating and announced a ...
news.stocktradersdaily20h
(CYTK) Technical Pivots with Risk Controls
Technical analysis for Cytokinetics Incorporated CYTK including support levels resistance levels and stop losses for CYTK ...
Yahoo Finance5d
Cytokinetics, Incorporated (CYTK)
Jan. 13, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Inc. (Nasdaq: CYTK) today provided guidance for corporate milestones expected to occur in 2025 and outlined its aspirational Vision 2030 ...
Nasdaq22d
Cytokinetics Grants Stock Options and Restricted Stock Units to New Employees as Inducement for Employment
Cytokinetics, Incorporated announced the granting of stock options and restricted stock units (RSUs) to nine new employees on December 31, 2024, as part of their employment inducement. The company ...
Cytokinetics’ Innovative CK-586 Advances Bolster Buy Rating Amid HFpEF Promise
H.C. Wainwright analyst Joseph Pantginis has reiterated their bullish stance on CYTK stock, giving a Buy rating on January 14.Invest with ...
Yahoo Finance8d
Cytokinetics Announces 2025 Corporate Milestones and Vision 2030
SOUTH SAN FRANCISCO, Calif., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Inc. (Nasdaq: CYTK) today provided guidance for corporate milestones expected to occur in 2025 and outlined its ...